Navigation Links
Pelikan Technologies Appoints Denny Ware to Board of Directors
Date:5/29/2008

Newest Board Member Brings Key Operational Experience and Broad Blood

Glucose Monitoring Industry Expertise

PALO ALTO, Calif., May 29 /PRNewswire/ -- Pelikan Technologies Inc., a leading developer of innovative hand-held diagnostic and monitoring devices, today announced the appointment of Dennert (Denny) Ware to its board of directors. Having most recently served as president and chief executive officer of Kinetic Concepts, Inc. (KCI), a global medical technology company, Mr. Ware brings vast operational and relevant industry experience to Pelikan's board. Under his leadership, revenue at KCI grew organically from approximately $300 million to $1.4 billion, making it one of the medical technology industry's fastest growing companies.

"We are very excited to have Denny join Pelikan's board," stated Pelikans president and chief executive officer, Dirk Boecker, M.D., Ph.D. "Not only does he have valuable first-hand experience in the blood glucose monitoring industry, he also has been responsible for generating tremendous revenue growth in the medical technology arena. This expertise will be particularly important for Pelikan as we ramp up our commercialization efforts for the Pelikan Sun(TM) electronic lancing device, as well as continue our development work on our next-generation, fully-integrated blood glucose system."

Prior to his work at KCI, Mr. Ware served as president and chief executive officer at Boehringer Mannheim Corporation, a market leader in the development and commercialization of innovative medical diagnostic equipment, particularly in the field of glucose monitoring and management for diabetics. Following Boehringer Mannheim's acquisition by F. Hoffman la Roche, he served as chief executive officer of Roche Diagnostics Corporation until joining KCI. Mr. Ware currently sits on the boards of Given Technologies, Inc., PharmacoPhotonics, Inc. and BioNumerik Pharmaceuticals, Inc.

"I am proud to join t
'/>"/>

SOURCE Pelikan Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
4. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, ... (IND) to conduct a pivotal Phase 3 clinical trial ... nontuberculous mycobacteria (NTM) lung infections has been cleared by ... In 2010, Insmed initially submitted a regulatory filing ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... pivotal trial of pixantrone for the treatment of relapsed/refractory ... now open to patient enrollment. The trial, referred to ... a combination of pixantrone plus rituximab to a combination ...
... Driving value for customers is critical to organizational success across ... customer and an organization, there has to be an integrated ... succeed in the marketplace. Chris Bogan, CEO ... in this month,s special issue of PharmaVoice that the state ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... has declined steadily in the last three decades. Although ... groups have shown some improvement, according to a recent ... the American Association for Cancer Research. "Our ... treatment, have resulted in profound gains, but these gains ...
... Barbara, Calif.) Scientists at UC Santa Barbara have found ... findings are published online in this week,s issue of the ... species differences in how they use the environment are key ... around us, but the importance of such niches have never ...
... the human brain reshapes itself to store this newfound knowledge. ... does that capacity to adapt reflect our risk for Alzheimer,s ... lives? Dr. Yaniv Assaf of Tel Aviv University,s Department ... effect of memory on brain structure. "With a specific MRI ...
Cached Biology News:Cancer mortality rates experience steady decline 2Scientists demonstrate importance of niche differences in biodiversity 2A window into the brain 2
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
NNT-1/BSF-3 (N-14)...
Biology Products: